Roche Holding Ltd · SIX:RO
Roche — AACC 2022 Analyst & Investor Event
31 slides from Roche's conference presentation, Jul 26, 2022
Slide 1: AACC – Diagnostics portfolio update
AACC – Diagnostics portfolio update Analyst & Investor Event Chicago, 26 July 2022
Slide 2: Agenda AACC
Agenda AACC Welcome Birgit Masjost, Investor Relations Officer Roche Diagnostics Financials Thomas Schinecker, CEO Roche Diagnostics Covid-19 updates Palani Kumaresan, Head of Research & Development Roche Diagnostics Solutions Recent launches Ann Costello, Global Head Roche Diagnostics Solutions Upc
Slide 3: Diagnostics of growing importance to Roche group
Diagnostics of growing importance to Roche group Structural growth driven by COVID-19 pandemic and investments in innovative technologies Sales Research & development Core operating profit Reaching ~1/3 of group sales Increased by +40%1 Doubled our contribution Diagnostics Diagnostics CHFm 899 Pharm
Slide 4: Financials
Financials Thomas Schinecker, CEO Roche Diagnostics
Slide 5: HY 2022: Group sales driven by both divisions
HY 2022: Group sales driven by both divisions 2022 2021 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 22.3 21.7 3 3 Diagnostics Division 9.9 9.0 10 11 Roche Group 32.3 30.7 5 5 CER=Constant Exchange Rates; totals may include differences due to rounding 5
Slide 6: HY 2022: Portfolio diversification progressing
HY 2022: Portfolio diversification progressing CHFm +5% at CER Diversification of Roche business +64 -987 HY 2017 HY 2022 +627 + 1,576 + 392 -90 CHF 26.3bn CHF 32.3bn AHR AHR 30,713 32,295 Diagnostics Oncology Other pharma AHR Ophthalmology Neuroscience Infectious diseases Hemophilia A HY Diagnostic
Slide 7: HY 2022: Diagnostics Division sales
HY 2022: Diagnostics Division sales Sales increase of +11% driven by COVID-19 testing and base business 2022 2021 Change in % CHFm CHFm CHF CER Diagnostics Division 9,948 9,042 10 11 Core Lab1 3,875 3,770 3 4 Point of Care1 2,609 1,798 45 46 Molecular Lab1 1,980 1,990 -1 1 Diabetes Care 832 894 -7 -
Slide 8: Diagnostics Division sales growth by quarter
Diagnostics Division sales growth by quarter Strong COVID-19 sales and base business growth Diagnostics Division sales growth 55% Base business sales growth 1 48% 28% 31% 24% 18% 17% 18% 9% 10% 5% 3% 2% -2% 11% 1% -5% 8% 0% Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 -17% 0.1bn 0.6bn
Slide 9: HY 2022: Diagnostics Division
HY 2022: Diagnostics Division Strong core operating profit growth of +11% 2022 2022 vs. 2021 CHFm % sales CER growth Sales 9,948 100 11% Royalties & other op. inc. 25 0.3 -46% Cost of sales -4,875 -49.1 14% M&D -1,363 -13.7 3% R&D -899 -9.0 11% G&A -276 -2.8 2% Core operating profit 2,560 25.7 11% +
Slide 10: COVID-19 Updates
COVID-19 Updates Palani Kumaresan, Head of Research & Development Roche Diagnostics Solutions
Slide 11: Our contribution against COVID-19
Our contribution against COVID-19 Roche has enabled access to >1.65 billion tests to fight the COVID-19 pandemic 20+ solutions >1.65 billion COVID-19 Responsible pricing to >1’900 cobas® 6800/8800 tests enable access instruments placed1 Broad portfolio of COVID-19 Conducted with our products Costs s
Slide 12: cobas SARS-CoV-2 DUO Emergency Use Authorisation
cobas® SARS-CoV-2 DUO Emergency Use Authorisation Providing accurate diagnosis of SARS-CoV-2 infection for proper patient management Dual target PCR design concept for accurate quantification Dual target design in SARS-CoV-2 virus specific region, for robust • Provide qualitative result of SARS-CoV-
Slide 13: Upcoming launch of Elecsys IGRA SARS-CoV-2
Upcoming launch of Elecsys® IGRA SARS-CoV-2 Improving the understanding of immunity against SARS-CoV-2 Testing workflow Step1 Step 2 T-Cell Stimulation Quantification of IFN-𝝲 • Detects T-cell mediated immune response by measuring IFN-γ (on Roche IA instrument) release upon stimulation with 189…
Slide 14: SARS-CoV-2 variants of concern & dominance of omicron BA.5
SARS-CoV-2 variants of concern & dominance of omicron BA.5 14 Source: U.S. CDC (Center for Disease Control and Prevention)
Slide 15: TIB-Molbiol SARS-CoV-2 menu for monitoring new variants
TIB-Molbiol SARS-CoV-2 menu for monitoring new variants Detecting major variants in hours vs a week for sequencing BA.1 & BA.1.1 XF BA.3 XE Delta BA.2 & BA.2.2 BA.2.12.1 BA.2.75 BA.5 BA.4 BA.5 is presently the dominant SARS-CoV-2 variant 15
Slide 16: Global emerging and re-emerging infectious diseases
Global emerging and re-emerging infectious diseases Most of new & emerging infections occur in LMICs with limited access to diagnostics Heartland Powassan virus Lyme Disease Drug-resistant malaria Diphtheria Enterovirus D68 Typhoid fever H3N2v influenza Cryptosporidiosis E. Coli 0104:H4 Akmeta Virus
Slide 17: Monkeypox assays supplied to WHO
Monkeypox assays supplied to WHO Three assays developed in record time to monitor epidemiologic spread of the virus LightMix® Modular Orthopox Viruses New Detects all orthopox viruses (e.g. monkeypox, cowpox, camelpox) LightMix® Modular Monkeypox Viruses New Detects all variants of monkeypox viruses
Slide 18: Recent launches
Recent launches Ann Costello, Global Head Roche Diagnostics Solutions
Slide 19: Elecsys HCV DUO Immunoassay
Elecsys® HCV DUO Immunoassay1 Early diagnosis of hepatitis C virus (HCV) enables optimal treatment Diagnostic window period2 • 58m people being chronically infected globally (80% unaware3) and about 1.5m new infections per year 6-12 weeks • Hepatitis C leading cause for liver cancer and curative rel
Slide 20: cobas HPV self-sampling solution
cobas® HPV self-sampling solution Increasing screening adherence to potentially reach 1.7bn women globally cobas® HPV self- cobas® HPV test CINtec® Plus Cytology CINtec® Histology iThemba Life® 342,000 women sampling solution1 die per year of cervical cancer, ~90% in LMIC with majority unscreened 2
Slide 21: BenchMark ULTRA PLUS system
BenchMark ULTRA PLUS system1 Next instrument generation for tissue advanced staining Optimized workflow Flexible solutions • Shortened reagent validation • View, manage, complete and print • Reduced turnaround time system data remotely • Fewer manual interventions • Optimized protocols and slide sta
Slide 22: VENTANA DP 600 slide scanner
VENTANA DP 600 slide scanner Enhancing digital pathology with high volume slide scanner High volume scanning Leverages optical system of DP 200 240 slide capacity (40x more than DP200) consistent image quality Flexible workflows Continuous loading improve efficiency walk-away automation Slide scanne
Slide 23: Upcoming launches
Upcoming launches Matt Sause, President & CEO Roche Diagnostics North America
Slide 24: New system launches in US
New system launches in US Enabling comparable results in different size laboratories Throughput cobas® pure cobas® pro cobas® pro (high throughput) Increasing access Serum Work Area Family concept addressing solutions needs of all lab sizes Reducing cost Automation and tailored throughput help labor
Slide 25: cobas mass spectrometry
cobas® mass spectrometry First fully integrated IVD platform for mass spectrometry creates a new market segment Seamless integration Increased patient access into routine testing to standardized mass spec technology Only integrated platform 50% of non-users would start on the market if integrated pl
Slide 26: Upcoming US approval of cobas pulse
Upcoming US approval of cobas® pulse1 Building an ecosystem for clinical decision support 3rd Party Apps3 Clinical decision Communication / support Documentation Offline test entry Digital Biomarkers Hospitals Pharmacies Sensor Reader ... GPs cobas® pulse cobas® infintiy edge SMART 2 Utilisation of
Slide 27: Breakthrough device designation for preeclampsia assays
Breakthrough device designation for preeclampsia assays Short-term prediction and appropriate management of preeclampsia Preeclampsia: 3-5% of all pregnancies disease with unpredictable onset and 4 clinical picture is not always clear1 difficult assessment of severity prognosis1 timely decision crit
Slide 28: Breakthrough device designation for Alzheimer's IVD blood tests
Breakthrough device designation for Alzheimer’s IVD blood tests Enabling access to Alzheimer’s disease modifying therapies Non-AD patients1 Patients undergoing initial evaluation for • pTau 181 and ApoE4 have been selected based on clinical non-specific cognitive decline AD patients1 performance and
Slide 29: Key launches 2022
Key launches 2022 Area Product Description Market Status Automated immunohistochemistry/in situ hybridization (ISH) advanced staining platform with BenchMark ULTRA PLUS US & CE Pathology Lab enhanced software capabilities, workflow and testing efficiency DP600 High capacity pathology slide scanner f
Slide 30: Q&A
Q&A
Slide 31: Doing now what patients need next
Doing now what patients need next